Tumor Heterogeneity and Drug Resistance in FGFR2-Fusion Cholangiocarcinoma
Demographics (1)
- SEX - Self-reported sex (phv00408879.v1.p1)
Disease Events (1)
- AFFECTION_STATUS - Case control status of the subject for cholangiocarcinoma (phv00408878.v1.p1)
Other (14)
- ACQUISITION_TYPE - Whether the tumor was collected as a biopsy or at autopsy (phv00408882.v1.p1)
- ANALYTE_TYPE - Analyte Type (phv00408884.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00408881.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00408874.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00408886.v1.p1)
- IS_TUMOR - Tumor status (phv00408885.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00408887.v1.p1)
- SAMPLE_ID - Sample ID (phv00408880.v1.p1)
- SAMPLE_ID - Sample ID (phv00408876.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00408888.v1.p1)
- SUBJECT_ID - Subject ID (phv00408877.v1.p1)
- SUBJECT_ID - Subject ID (phv00408873.v1.p1)
- SUBJECT_ID - Subject ID (phv00408875.v1.p1)
- TREATMENT - Whether the tumor is pre- or post-FGFR2 inhibitor treatment (phv00408883.v1.p1)